Inflammatory and prothrombotic parameters in normotensive non-diabetic obese women: Effect of weight loss obtained by gastric banding

Internal and Emergency Medicine

Volumn 7, Issue 3, 2012, Pages 237-242

  Cugno, Massimo ^a   Castelli, Roberto ^a   Mari, Daniela ^a   Mozzi, Enrico ^a   Zappa, Marco Antonio ^a   Boscolo Anzoletti, Massimo ^a   Roviaro, Giancarlo ^a   Mannucci, Pier Mannuccio ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Coagulation; Gastric banding; Inflammation; Obesity; Thrombotic risk

Indexed keywords

BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CLOTTING; BODY MASS; FEMALE; GASTROPLASTY; HUMAN; INFLAMMATION; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; OBESITY; PATHOLOGY; RISK FACTOR; WEIGHT REDUCTION; WOMEN'S HEALTH;

ADULT; BLOOD COAGULATION; BODY MASS INDEX; C-REACTIVE PROTEIN; FACTOR VII; FEMALE; FIBRINOGEN; GASTROPLASTY; HUMANS; INFLAMMATION; MIDDLE AGED; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; STATISTICS, NONPARAMETRIC; VON WILLEBRAND FACTOR; WEIGHT LOSS; WOMEN'S HEALTH;

EID: 84862219660     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-011-0522-x     Document Type: Article

References (36)

1. Jousilahti P, Tuomilehto J, Vartiainen E, Pekkanen J, Puska P (1996) Body weight, cardiovascular risk factors, and coronary mortality: 15-year follow-up of middle-aged men and women in Eastern Finland. Circulation 93: 1372-1379.
2. van Gaal LF, Mertens IL, De Block CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444: 875-880.
3. Rosito GA, D'Agostino RB, Massaro J, Lipinska I, Mittleman MA, Sutherland P et al (2004) Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 91: 683-689.
4. Arnlöv J, Ingelsson E, Sundström J, Lind L (2010) Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 121: 230-236.
5. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102: 42-47.
6. Esmon CT (2004) The impact of the inflammatory response on coagulation. Thromb Res 114: 321-327.
7. Dietrich M, Jialal I (2005) The effect of weight loss on a stable biomarker of inflammation, C-reactive protein. Nutr Rev 63: 22-28.
8. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L et al (1990) Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 39: 1044-1048.
9. Trayhurn P, Wood IS (2005) Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans 33: 1078-1081.
10. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR et al (2008) Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 117: 2253-2261.
11. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB et al (1994) The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331: 417-424.
12. Boekholdt SM, Kastelein JJ (2010) C-reactive protein and cardiovascular risk: more fuel to the fire. Lancet 375: 95-96.
13. Wolk R, Berger P, Lennon RJ, Brilakis ES, Somers VK (2003) Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation 108: 2206-2211.
14. Mathieu P, Lemieux I, Després JP (2010) Obesity, inflammation, and cardiovascular risk. Clin Pharmacol Ther 87: 407-416.
15. Selvin E, Paynter NP, Erlinger TP (2007) The effect of weight loss on C-reactive protein: a systematic review. Arch Intern Med 167: 31-33.
16. Belachew M, Legrand M, Vincent V, Deffechereux T, JourdanJL MonamiB et al (1995) Laparoscopic placement of adjustable silicone gastric band in the treatment of morbid obesity: how to do it. Obes Surg 5: 66-70.
17. De Maria EJ (2007) Bariatric surgery for morbid obesity. N Engl J Med 356: 2176-2183.
18. Cobourn C, Mumford D, Chapman MA, Wells L (2010) Laparoscopic gastric banding is safe in outpatient surgical centers. ObesSurg 20: 415-422.
19. Mannucci PM, Coppola R. (1999) von Willebrand factor. In: Jespersen J, Bertina RM, Haverkate F (eds) Laboratory techniques in thrombosis. A Manual. Kluwer Academic Publishers, Boston, pp 115-119.
20. Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease. The Framingham study. JAMA 241: 2035-2038.
21. Primrose JN, Davies JA, Prentice CR (1992) Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb Hemost 68: 396-399.
22. Licata G, Scaglione R, Avellone G, Ganguzza A, Corrao S, Arnone S et al (1995) Hemostatic function in young subjects with central obesity: relationship with left ventricular function. Metabolism 44: 1417-1421.
23. Rillaerts E, Vansant G, van Gaal L, DeLeeuw I (1989) Effect of weight reduction on blood viscosity parameters in obese women. Clin Hemorheol l9: 983-987.
24. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC et al (1986) Correlation between fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 35: 250-253.
25. Hamsten A, Walldius G, Szamosi A, Blombäck M, de Faire U, Dahlén G et al (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2: 3-8.
26. Jansson JH, Olofsson BO, Nilsoon TK (1993) Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 88: 2030-2034.
27. Bouchard L, Vohl MC, Lebel S, Hould FS, Marceau P, Bergeron J et al (2010) Contribution of genetic and metabolic syndrome to omental adipose tissue PAI-1 Gene mRNA and plasma levels in obesity. Obes Surg 20: 492-499.
28. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G et al. (1993) Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 70: 380-38.
29. De Pergola G, De Mitrio V, Giorgino F, Sciaraffia M, Minenna A, Di Bari L et al (1997) Increase in both prothrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution. Int J Obes 21: 527-535.
30. Blann AD, Bushell D, Davies A, Faragher EB, Miller JP, McCollum CN (1993) von Willebrand factor, the endothelium and obesity. Int J Obes 17: 723-725.
31. Folsom AR, Qamhieh HT, Wing RR, Jeffery RW, Strinson VL, Kuller LH et al (1993) Impact of weight loss on plasminogen activator inhibitor (PAI1), factor VII, and other hemostatic factors in moderately overweight adults. Atherioscler Thromb 13: 162-169.
32. Faber DR, de Groot PG, Visseren FL (2009) Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obes Rev 10: 554-563.
33. Levi M, van der Poll T, Büller HR (2004) Bidirectional relation between inflammation and coagulation. Circulation 109: 2698-2704.
34. Targher G, Zoppini G, Moghetti P, Day CP (2010) Disorders of coagulation and hemostasis in abdominal obesity: emerging role of fatty liver. Semin Thromb Hemost 36: 41-48.
35. Svendsen OL, Hassager C, Christiansen C, Nielsen JD, Winther K (1996) Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen. Effect of dieting with or without exercise in overweight postmenopausal women. Arterioscerl Thromb Vasc Biol 16: 381-385.
36. Mertens I, van Gaal LF (2002) Obesity, haemostasis and the fibrinolytic system. Obes Rev 3: 85-101.